AI Article Synopsis

  • Rheumatoid arthritis (RA) is a challenging inflammatory disease, particularly for patients unresponsive to standard treatments, but options like adalimumab (ADA) exist for management.
  • This report details the first successful case of a 60-year-old woman with both RA and HIV, who achieved clinical remission after a year of adalimumab therapy combined with highly active antiretroviral therapy (HAART).
  • The findings suggest that adalimumab is safe for RA patients with HIV and may help manage symptoms while also potentially slowing HIV progression.

Article Abstract

Unlabelled: Rheumatoid arthritis (RA) is a joint-disabling inflammatory disease associated with the pathology of synovitis. Some patients with RA are difficult to treat, using disease-modifying anti-rheumatic drugs (DMARDs). Biology and targeted synthetic DMARDs (b/tsDMARDs) are options for patients with RA. Acquired immunodeficiency syndrome (AIDS) is an infectious disease caused by the human immunodeficiency virus (HIV). Adalimumab is an anti-tumor necrosis factor therapy commonly used in patients with RA. However, there are no reports or related data on patients with RA-HIV/AIDS treated with adalimumab are available. In this report, we described the first successful case of a 60-year-old HIV-positive woman with difficult-to-treat RA treated with ADA after being screened for hepatitis virus, latent tuberculosis (LTBI), and other infections. She contracted HIV from sexual exposure while on adalimumab therapy. As the patient was resistant to first-line DMARDs, she continued adalimumab along with the initiation of highly active antiretroviral therapy (HAART). The patient was treated with adalimumab therapy for a year; her CD4+ lymphocyte count was normal, HIV-1 RNA decreased, and no new infections were triggered. The patient achieved clinical remission of RA. In conclusion, adalimumab is a safe option for patients with RA-HIV and may slow the progression of HIV infection. Furthermore, HAART has the potential to reduce joint pain and fatigue in patients with difficult-to-treat RA.

Conclusions: Adalimumab is a safe option for patients with RA-HIV, and may slow down the progression of HIV infection. The HAART therapy has the potential to reduce joint pain and fatigue in patients with difficult-to-treat RA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382239PMC
http://dx.doi.org/10.3389/fimmu.2022.942642DOI Listing

Publication Analysis

Top Keywords

adalimumab
8
rheumatoid arthritis
8
human immunodeficiency
8
patients
8
treated adalimumab
8
adalimumab therapy
8
adalimumab safe
8
safe option
8
option patients
8
patients ra-hiv
8

Similar Publications

Purpose: To report a case of bilateral choroidal osteoma successfully treated with subscleral sclerectomy for secondary serous retinal detachment (SRD).

Observations: A 52-year-old Japanese woman first diagnosed with Vogt-Koyanagi-Harada disease and treated with steroids for 9 years was referred to our clinic. SRD in both eyes recurred frequently and was uncontrolled with adalimumab subcutaneous injections and oral cyclosporine, in addition to steroids.

View Article and Find Full Text PDF

Objectives: The usefulness of methotrexate-polyglutamates (MTX-PGs) concentration for management of rheumatoid arthritis has been debated. We aimed to clarify the association of MTX-PGs concentration with efficacy and safety in MTX-naïve patients initiating MTX in a prospective interventional clinical trial.

Methods: The MIRACLE trial enrolled 300 MTX-naïve patients.

View Article and Find Full Text PDF

Multiple parameters define the treatment course with biologics for a psoriatic patient while treatment switches are often associated with worse prognosis. The purpose of this study was to describe the switching patterns of biologics for psoriasis in the Greek market landscape and to detect associated factors that may impact the evolvement of selected therapy. This is a retrospective cohort study using data recorded in the nationwide digital prescription database of Greece.

View Article and Find Full Text PDF

Objectives: Mucosal healing (MH) is a key therapeutic target in Crohn's disease (CD) and is associated with improved outcomes. While adult studies indicate a positive correlation between serum anti-tumor necrosis factor (TNF) levels and MH, data in pediatric patients is limited. We aimed to define the association of serum anti-TNF levels with MH in pediatric patients with CD during maintenance therapy.

View Article and Find Full Text PDF

The biopharmaceutical industry has witnessed significant growth in the development and approval of biosimilars. These biosimilars aim to provide cost-effective alternatives to expensive originator biosimilars, alleviating financial pressures within healthcare. The manufacturing of biosimilars is a highly complex process that involves several stages, each of which must meet strict regulatory standards to ensure that the final product is highly similar to the reference biologic.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!